AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31410626 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE) added to endoscopic ultrasound fine-needle aspiration (EUS-FNA)
Number of subjects: 206
Study 31410626 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE)
Number of subjects: 206
Study 31410738 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT success (n=61)
Number of subjects: 78
Study 31410738 — intervention group
Group type: COMPARATOR
Intervention: SBT failure (n=17)
Number of subjects: 78
Study 31410738 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation success (n=39)
Number of subjects: 78
Study 31410779 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2i)
Number of subjects: 455662
Study 31410787 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg once daily
Number of subjects: 611
Study 31410992 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli soup (300 mL portions, three times a week for four weeks)
Number of subjects: 18
Study 31410992 — intervention group
Group type: COMPARATOR
Intervention: Control (no broccoli soup)
Number of subjects: 18
Study 31411386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (single intravenous dose ≤20 mg/kg or 2 consecutive doses of 10 mg/kg given 84 days apart)
Number of subjects: 1607
Study 31411386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (single 10 mg/kg dose)
Number of subjects: 1607
Study 31411386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (in phase 3 trials)
Number of subjects: 1607
Study 31411949 — intervention group
Group type: EXPERIMENTAL
Intervention: De-intensified chemoradiotherapy regimen of 60 Gy intensity-modulated radiotherapy with concurrent intravenous cisplatin 30 mg/m²
Number of subjects: 114
Study 31411949 — intervention group
Group type: EXPERIMENTAL
Intervention: De-intensified chemoradiotherapy regimen
Number of subjects: 114
Study 31412732 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 803
Study 31412789 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exchange (WE) with near-complete removal of infused water (89%) during insertion
Number of subjects: 86
Study 31412789 — intervention group
Group type: COMPARATOR
Intervention: Water exchange (WE)
Number of subjects: 86
Study 31412834 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Exercise Questionnaire (PEQ)
Number of subjects: 95
Study 31412836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue force-of-infection estimation
Number of subjects: 2556
Study 31412836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue infection rates
Number of subjects: 2556
Study 31412836 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of primary dengue infections
Number of subjects: 2556
Study 31412874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 33
Study 31412874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31412906 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring regional cerebral oxygen saturation (rSO2)
Number of subjects: 0
Study 31412935 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8895a (20 mg/kg) infused intravenously every 2 weeks
Number of subjects: 37
Study 31413142 — intervention group
Group type: EXPERIMENTAL
Intervention: Veledimex (VDX) 20 mg
Number of subjects: 31
Study 31413142 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (dexamethasone) >20 mg
Number of subjects: 31
Study 31413142 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (dexamethasone) ≤20 mg
Number of subjects: 31
Study 31413142 — intervention group
Group type: COMPARATOR
Intervention: Veledimex (VDX) 20 mg cohort with corticosteroids >20 mg
Number of subjects: 31
Study 31413142 — intervention group
Group type: COMPARATOR
Intervention: Veledimex (VDX) 20 mg cohort with corticosteroids ≤20 mg
Number of subjects: 31
Study 31413142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12
Number of subjects: 31
Study 31413177 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP1 inhibition using AZD2281-olaparib and ABT-888-veliparib
Number of subjects: 0
Study 31413844 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of patients with AS in tertiary care settings
Number of subjects: 800
Study 31413844 — intervention group
Group type: COMPARATOR
Intervention: Management of patients with AS in primary/secondary care settings
Number of subjects: 800
Study 31413844 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from asymptomatic to symptomatic status
Number of subjects: 800
Study 31413844 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic steps and treatment decisions
Number of subjects: 800
Study 31413865 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line TNF inhibitors (TNFis)
Number of subjects: 203
Study 31413865 — intervention group
Group type: COMPARATOR
Intervention: Other biological agents (tocilizumab (TCZ), rituximab, or abatacept)
Number of subjects: 203
Study 31413865 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab (TCZ)
Number of subjects: 203
Study 31413923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexa-Vec plus Best Supportive Care (BSC)
Number of subjects: 129
Study 31413923 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC) alone
Number of subjects: 129
Study 31413923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexa-Vec plus BSC
Number of subjects: 129
Study 31413963 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPP (Strength, Agility, Plyometric, and Secondary Prevention exercises)
Number of subjects: 40
Study 31413963 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPP + PERT (SAPP with Perturbation Training)
Number of subjects: 40
Study 31413963 — intervention group
Group type: COMPARATOR
Intervention: Criterion-based postoperative rehabilitation (MOON)
Number of subjects: 40
Study 31413963 — intervention group
Group type: COMPARATOR
Intervention: Criterion-based postoperative rehabilitation with extended preoperative rehabilitation (Delaware-Oslo)
Number of subjects: 40
Study 31414072 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded Vegetable Questionnaire
Number of subjects: 0
Study 31414121 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-benefit analysis using rank-based method
Number of subjects: 0
Study 31414121 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-benefit analysis using partial-credit method
Number of subjects: 0
Study 31414251 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstressed spontaneous breathing (baseline)
Number of subjects: 13
Study 31414251 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressed spontaneous breathing (with resistance)
Number of subjects: 13
Study 31414251 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted spontaneous breathing (pressure support at low and high assist levels)
Number of subjects: 13
Study 31414251 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted spontaneous breathing (neurally adjusted ventilatory assist - NAVA)
Number of subjects: 13
Study 31414251 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of Eadi, breathing pattern, esophageal pressure-time product (PTPeso), and work of breathing (WOB)
Number of subjects: 13
Study 31414348 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational palliative care intervention
Number of subjects: 195
Study 31414348 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study 31414396 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) adherence strategies informed by shared decision-making (SDM)
Number of subjects: 46
Study 31414396 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) adherence strategies
Number of subjects: 46
Study 31414396 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention
Number of subjects: 46
Study 31415245 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive lymphocyte transfer from an elite controller (approximately 22 billion cells infused within 6 hours)
Number of subjects: 1
Study 31415245 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive lymphocyte transfer from an elite controller
Number of subjects: 1
Study 31415351 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-surgery (meshectomy/selective neurectomy)
Number of subjects: 172
Study 31415351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 172
Study 31415416 — intervention group
Group type: EXPERIMENTAL
Intervention: Shujinjianyao pill (SJJYP) for 4 weeks
Number of subjects: 0
Study 31415566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox (NF) treatment for Chagas disease, median dose 9.75 mg/kg/day three times a day (TID) for 1 month
Number of subjects: 10
Study 31415936 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH, DHEA, LH
Number of subjects: 45
Study 31415936 — intervention group
Group type: EXPERIMENTAL
Intervention: LH
Number of subjects: 45
Study 31415936 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH
Number of subjects: 45
Study 31415936 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 45
Study 31416443 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcome Measures (PROMs) questionnaires administered before surgery, at 6 months, and at 12 months post-surgery
Number of subjects: 0
Study 31416527 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC hs-cTnT 0/1 h algorithm
Number of subjects: 3123
Study 31416527 — intervention group
Group type: COMPARATOR
Intervention: Extended algorithm
Number of subjects: 3123
Study 31416921 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated training on joint assessment
Number of subjects: 0
Study 31416921 — intervention group
Group type: COMPARATOR
Intervention: Single training on joint assessment
Number of subjects: 0
Study 31416921 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-performed assessments of joints and DAS28-CRP
Number of subjects: 0
Study 31417440 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Cognitive-Behavioral Therapy
Number of subjects: 0
Study 31417958 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) combined with systemic chemotherapy
Number of subjects: 66
Study 31417958 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy alone
Number of subjects: 66
Study 31418129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with Autism Spectrum Disorder (ASD)
Number of subjects: 0
Study 31418129 — intervention group
Group type: COMPARATOR
Intervention: Typically developed adults (TD)
Number of subjects: 0
Study 31419019 — intervention group
Group type: EXPERIMENTAL
Intervention: Melody transcatheter pulmonary valve replacement (TPVR)
Number of subjects: 409
Study 31419065 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1R-AA >40 U/mL
Number of subjects: 94
Study 31419065 — intervention group
Group type: COMPARATOR
Intervention: AT1R-AA <40 U/mL
Number of subjects: 94
Study 31419065 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased concentrations of AT1R-AA
Number of subjects: 94
Study 31419329 — intervention group
Group type: EXPERIMENTAL
Intervention: THN102 100/1
Number of subjects: 20
Study 31419329 — intervention group
Group type: EXPERIMENTAL
Intervention: THN102 100/1, 100/3, 100/9
Number of subjects: 20
Study 31419329 — intervention group
Group type: EXPERIMENTAL
Intervention: THN102 100/1 and 100/9
Number of subjects: 20
Study 31419329 — intervention group
Group type: EXPERIMENTAL
Intervention: THN102
Number of subjects: 20
Study 31419329 — intervention group
Group type: COMPARATOR
Intervention: MOD100
Number of subjects: 20
Study 31419329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 20
Study 31420042 — intervention group
Group type: EXPERIMENTAL
Intervention: SM04690, a small-molecule inhibitor of the Wnt signaling pathway
Number of subjects: 0
Study 31420052 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg raising (ΔCRT-PLR)
Number of subjects: 34
Study 31420052 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume expansion
Number of subjects: 34
Study 31420056 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' predictions upon ICU admission
Number of subjects: 252
Study 31420056 — intervention group
Group type: COMPARATOR
Intervention: AKIpredictor upon ICU admission
Number of subjects: 252
Study 31420056 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' predictions on the first morning
Number of subjects: 252
Study 31420056 — intervention group
Group type: COMPARATOR
Intervention: AKIpredictor on the first morning
Number of subjects: 252
Study 31420056 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' predictions after 24 hours
Number of subjects: 252
Study 31420056 — intervention group
Group type: COMPARATOR
Intervention: AKIpredictor after 24 hours
Number of subjects: 252
Study 31420317 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (bodyweight-adjusted 20 mg-equivalent dose) administered orally; dosing regimens: once-daily for ages 6-17 years, twice-daily for ages 6 months to 11 years, three times-daily for ages younger than 6 months; duration of treatment: 30 days (or 7 days for those younger than 6 months).
Number of subjects: 93
Study 31420317 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (bodyweight-adjusted)
Number of subjects: 93
Study 31420358 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg every 2 weeks
Number of subjects: 75
Study 31420379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low dose (ULD) chest CT using ASiR-V
Number of subjects: 150
Study 31420379 — intervention group
Group type: COMPARATOR
Intervention: Standard low-dose (LD) CT
Number of subjects: 150
Study 31420379 — intervention group
Group type: EXPERIMENTAL
Intervention: ULD CT with 50% and 100% ASiR-V
Number of subjects: 150
Study 31420379 — intervention group
Group type: COMPARATOR
Intervention: LD CT with 50% ASiR-V
Number of subjects: 150
Study 31420387 — intervention group
Group type: EXPERIMENTAL
Intervention: End-ischaemic DHOPE followed by COR and NMP
Number of subjects: 0
Study 31420462 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematoma surface
Number of subjects: 300
Study 31420462 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematoma volume
Number of subjects: 300
Study 31420462 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak perihemorrhagic edema
Number of subjects: 300
Study 31420462 — intervention group
Group type: EXPERIMENTAL
Intervention: Edema-modifying therapies
Number of subjects: 300
Study 31420846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 323
Study 31420846 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 323
Study 31420849 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium-YAG laser (6 sessions over 6 months)
Number of subjects: 75
Study 31420849 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (12 sessions over 6 months)
Number of subjects: 75
Study 31420849 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Erbium-YAG laser plus Platelet-rich plasma, 6 sessions of laser and 12 sessions of plasma over 6 months)
Number of subjects: 75
Study 31421008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC)
Number of subjects: 70
Study 31421008 — intervention group
Group type: COMPARATOR
Intervention: King's College Criteria (KCC) with declining AFP levels
Number of subjects: 70
Study 31421008 — intervention group
Group type: EXPERIMENTAL
Intervention: Gc globulin
Number of subjects: 70
Study 31421023 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray-scale synovitis severity (grade 2-3)
Number of subjects: 290
Study 31421023 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Doppler activity
Number of subjects: 290
Study 31421023 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Doppler activity in CMC1
Number of subjects: 290
Study 31421023 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation in CMC1 joints
Number of subjects: 290
Study 31421111 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural Sedation (PS)
Number of subjects: 30
Study 31421111 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 30
Study 31421324 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms and anxiety (measured by Beck Depression Inventory BDI and Hospital Anxiety and Depression Scale HADS)
Number of subjects: 524
Study 31421324 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms and anxiety
Number of subjects: 524
Study 31421471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescently labeled anti-EGFR antibody (panitumumab-IRDye800CW)
Number of subjects: 11
Study 31421641 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolic stroke of undetermined source (ESUS) patients
Number of subjects: 90
Study 31421641 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 90
Study 31421657 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET-CT
Number of subjects: 130
Study 31421933 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose apixaban 2.5mg BID
Number of subjects: 6306
Study 31421933 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose apixaban 5mg BID
Number of subjects: 6306
Study 31421933 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended reduced-dose group
Number of subjects: 6306
Study 31421933 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-recommended reduced-dose group
Number of subjects: 6306
Study 31422088 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-EES (Biodegradable Polymer Everolimus-Eluting Stent)
Number of subjects: 1041
Study 31422088 — intervention group
Group type: COMPARATOR
Intervention: DP-EES (Durable Polymer Everolimus-Eluting Stent)
Number of subjects: 1041
Study 31422088 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-EES
Number of subjects: 1041
Study 31422088 — intervention group
Group type: COMPARATOR
Intervention: DP-EES
Number of subjects: 1041
Study 31422126 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT-PET
Number of subjects: 0
Study 31422126 — intervention group
Group type: COMPARATOR
Intervention: FDG/Perfusion-PET
Number of subjects: 0
Study 31422129 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast ultrasound with intravenous microbubble infusion for 10 min
Number of subjects: 0
Study 31422129 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US) alone
Number of subjects: 0
Study 31422137 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA advanced plaque assessment
Number of subjects: 544
Study 31422137 — intervention group
Group type: EXPERIMENTAL
Intervention: Low noncalcified plaque volume
Number of subjects: 544
Study 31422137 — intervention group
Group type: EXPERIMENTAL
Intervention: High noncalcified plaque volume
Number of subjects: 544
Study 31422137 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA assessment
Number of subjects: 544
Study 31422141 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-FFR
Number of subjects: 314
Study 31422759 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (eventual abstainers)
Number of subjects: 188
Study 31422759 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking (continued smokers)
Number of subjects: 188
Study 31423298 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants fed a modified gut microbiome
Number of subjects: 2
Study 31423298 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study 31425221 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor Epidural Analgesia (LEA)
Number of subjects: 1204
Study 31425221 — intervention group
Group type: COMPARATOR
Intervention: No Labor Epidural Analgesia (Control)
Number of subjects: 1204
Study 31425221 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous breastfeeding experience
Number of subjects: 1204
Study 31425273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis-3
Number of subjects: 21191
Study 31425273 — intervention group
Group type: COMPARATOR
Intervention: Severe sepsis/septic shock
Number of subjects: 21191
Study 31425273 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired infections
Number of subjects: 21191
Study 31425366 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental formula
Number of subjects: 0
Study 31425735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 0
Study 31425735 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 0
Study 31425735 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 0
Study 31425781 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (40 mg for <40 kg or 100 mg for ≥40 kg) administered subcutaneously over 52 weeks
Number of subjects: 30
Study 31425781 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab treatment
Number of subjects: 30
Study 31426671 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite smoking cessation services
Number of subjects: 0
Study 31426671 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard smoking cessation services)
Number of subjects: 0
Study 31426771 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive option (multiple interventions including online menus, health challenges, support in creating a healthy work environment, coaching by health professionals, health screening, flexibility assessment, online resources, social health platform, activity tracking)
Number of subjects: 0
Study 31426771 — intervention group
Group type: COMPARATOR
Intervention: Limited option (control group, consisting only of completing a questionnaire regarding health status, lifestyle habits, and behaviors)
Number of subjects: 0
Study 31427096 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrostomy tube placement (GT), 333 infants (7.3% of ELBW infants), 76% postdischarge.
Number of subjects: 4549
Study 31427096 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrostomy tube placement (GT)
Number of subjects: 4549
Study 31427205 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily with dose titration every 14 days up to 10 mg twice daily)
Number of subjects: 40
Study 31427205 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily with dose titration)
Number of subjects: 40